Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$558M |
| 2 |
Apple
AAPL
|
+$265M |
| 3 |
Microsoft
MSFT
|
+$209M |
| 4 |
Amazon
AMZN
|
+$197M |
| 5 |
Visa
V
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COHR
Coherent Inc
COHR
|
+$86.3M |
| 2 |
TSMC
TSM
|
+$77.2M |
| 3 |
iShares MBS ETF
MBB
|
+$44.5M |
| 4 |
KSU
Kansas City Southern
KSU
|
+$43.8M |
| 5 |
Vale
VALE
|
+$28.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.97% |
| 2 | Financials | 12.67% |
| 3 | Consumer Discretionary | 11.32% |
| 4 | Healthcare | 10.27% |
| 5 | Communication Services | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Amphenol
APH
$211B
| $621K | ﹤0.01% |
18,148
+824
| +5% | +$27.8K |
|
602
Gilead Sciences
GILD
$164B
| $620K | ﹤0.01% |
9,003
-260
| -3% | -$17.4K |
|
603
Waste Management
WM
$90B
| $606K | ﹤0.01% |
4,323
+294
| +7% | +$40.6K |
|
604
Casella Waste Systems
CWST
$5.81B
| $602K | ﹤0.01% |
9,491
-118
| -1% | -$7.83K |
|
605
Camden Property Trust
CPT
$11B
| $585K | ﹤0.01% |
4,409
-616
| -12% | -$76.4K |
|
606
Enterprise Products Partners
EPD
$82.6B
| $582K | ﹤0.01% |
24,126
+12,167
| +102% | +$288K |
|
607
Wabtec
WAB
$50.5B
| $581K | ﹤0.01% |
7,054
-1,046
| -13% | -$84.9K |
|
608
Red Robin
RRGB
$150M
| $580K | ﹤0.01% |
+17,508
| New | +$597K |
|
609
VeriSign
VRSN
$27B
| $578K | ﹤0.01% |
2,538
+3
| +0.1% | +$653 |
|
610
eBay
EBAY
$48.3B
| $577K | ﹤0.01% |
8,221
+142
| +2% | +$8.9K |
|
611
iShares Core S&P Small-Cap ETF
IJR
$113B
| $575K | ﹤0.01% |
5,089
+1,668
| +49% | +$186K |
|
612
iShares Broad USD Investment Grade Corporate Bond ETF
USIG
$17.4B
| $569K | ﹤0.01% |
9,396
+1,656
| +21% | +$98.9K |
|
613
iShares US Aerospace & Defense ETF
ITA
$14.7B
| $564K | ﹤0.01% |
5,153
-492
| -9% | -$53K |
|
|
IMGN
614
DELISTED
Immunogen Inc
IMGN
| $561K | ﹤0.01% |
85,069
+43,127
| +103% | +$301K |
|
615
Cencora
COR
$59.4B
| $560K | ﹤0.01% |
4,894
-433
| -8% | -$51.2K |
|
616
iShares Russell 1000 Value ETF
IWD
$83.4B
| $559K | ﹤0.01% |
3,523
+1,228
| +54% | +$194K |
|
617
First Trust Nasdaq-100 Select Equal Weight ETF
QQEW
$1.82B
| $558K | ﹤0.01% |
4,970
+3
| +0.1% | +$321 |
|
|
THS
618
DELISTED
Treehouse Foods
THS
| $553K | ﹤0.01% |
12,422
| – | – |
|
619
Designer Brands
DBI
$337M
| $544K | ﹤0.01% |
+32,894
| New | +$579K |
|
620
Vanguard Extended Market ETF
VXF
$31.6B
| $543K | ﹤0.01% |
+2,877
| New | +$526K |
|
621
Heron Therapeutics
HRTX
$101M
| $542K | ﹤0.01% |
34,907
+185
| +0.5% | +$2.94K |
|
622
iShares MSCI Germany ETF
EWG
$1.62B
| $539K | ﹤0.01% |
15,564
-903
| -5% | -$31.7K |
|
623
Vanguard Tax-Exempt Bond Index Fund
VTEB
$45.2B
| $535K | ﹤0.01% |
9,676
-956
| -9% | -$52.7K |
|
624
Blackstone
BX
$110B
| $525K | ﹤0.01% |
5,408
+2,605
| +93% | +$231K |
|
|
IFX
625
DELISTED
INFINEON TECH AG ADS(REP1 ORD)
IFX
| $520K | ﹤0.01% |
12,956
-81
| -0.6% | -$3.25K |
|
Similar funds
Ken Fisher's Q2 2021 Portfolio in Review
As of Q2 2021, Ken Fisher held 1,100 positions worth $159B, up 12% from $142B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Ken Fisher deployed $4.92B of net new capital in Q2 2021, opening 101 new positions and adding to 388 existing holdings. Its largest new stake was Organon & Co: 967,460 shares worth $29.3M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was TSMC, an estimated $77.2M trimmed.
- Ken Fisher's largest Q2 2021 buy was Organon & Co: 967,460 shares worth $29.3M.
- Ken Fisher added most to Vanguard Intermediate-Term Corporate Bond ETF in Q2 2021, an estimated $558M increase.
- Ken Fisher's biggest Q2 2021 reduction was TSMC, cutting an estimated $77.2M.
- Ken Fisher fully exited Coherent Inc in Q2 2021, selling an estimated $86.3M.
- Ken Fisher's ten largest holdings make up 32% of its $159B portfolio in Q2 2021.
- Ken Fisher opened 101 new positions and closed 90 in Q2 2021.
- Ken Fisher's portfolio value rose 12% quarter-over-quarter to $159B.
Based on Fisher Asset Management's 13F filing for Q2 2021, filed 27 Jul 2021.